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Development of oral controlled-release systems has been a challenge to formulation
scientists because of their inability to restrain and localize the system in the targeted
area of the gastrointestinal tract. Controlled/sustained release preparations using alter-
native routes have been formulated but the oral route still remains preferable. When the
drug is formulated with a gel forming polymer such as semisynthetic derivatives of cel-
lulose, it swells in the gastric fluid with a bulk density less than one. It then remains
buoyant and floats in the gastric fluid, affecting a prolonged gastric residence time (GRT).
This floating dosage form is well known as a hydrodynamically balanced system (HBS)
(1–3). It has been suggested for the following instances that an active material should be
formulated in the form of an HBS to enhance bioavailability: (i) having a dissolution
and/or stability problem in the small intestine fluids, (ii) being locally effective in the
stomach, (iii) being absorbed only in the stomach and/or upper part of the intestine (4).
Floating tablets, capsules, beads, microspheres and chambers have been reported in lite-
rature (5).
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The objective of the present investigation was to develop
a bilayer-floating tablet (BFT) for captopril using direct
compression technology. HPMC, K-grade and efferves-
cent mixture of citric acid and sodium bicarbonate formed
the floating layer. The release layer contained captopril
and various polymers such as HPMC-K15M, PVP-K30
and Carbopol 934p, alone or in combination with the drug.
The floating behavior and in vitro dissolution studies were
carried out in a USP 23 apparatus 2 in simulated gastric
fluid (without enzyme, pH 1.2). Final formulation released
approximately 95% drug in 24 h in vitro, while the floating
lag time was 10 min and the tablet remained floatable
throughout all studies. Final formulation followed the
Higuchi release model and showed no significant change
in physical appearance, drug content, floatability or in vitro
dissolution pattern after storage at 45 °C/75% RH for
three months. Placebo formulation containing barium
sulphate in the release layer administered to human vol-
unteers for in vivo X-ray studies showed that BFT had
significantly increased the gastric residence time.
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Captopril, an antihypertensive agent, has been widely used for the treatment of hy-
pertension and congestive heart failure. It has been reported, however, that the duration
of antihypertensive action after a single oral dose of captopril is only 6–8 h, so clinical
use requires a daily dose of 37.5–75 mg to be taken three times (6). It is most stable at pH
1.2 and as the pH increases, it becomes unstable and undergoes a degradation reaction
(7). The virtue of the prolonged release dosage form of captopril has been reviewed (8).
Researchers have developed a single layer floating tablet of captopril (9). In comparison
with the single layer tablet, a double layer matrix offers advantages; this formulation of
the matrix dosage form with two distinct layers allows separate regulation of the float-
ing capabilities and drug release kinetics (5). The present investigation aims to develop a
BFT of captopril with a view of prolonging GRT with a controlled release mechanism.
EXPERIMENTAL
Materials
Captopril (99.98% purity, Batch No-C10604) was obtained as a gift sample from Lupin
Pharmaceuticals, India. HPMC-K4M and HPMC-K15M were obtained from the Dabur
Research Foundation, India. Ranbaxy Laboratories Ltd., India, kindly donated HPMC-
-K100M, Carbopol 934p and PVP-K30. All the polymers received were of pharmaceuti-
cal grade and were used as received. Other materials and solvents used were of analyti-
cal grade or better. All the studies were carried in HPLC grade water.
Formulation
Floating layer. – Various floating layer formulations were formulated with HPMC-
-K4M, HPMC-K15M and HPMC-K100M polymers alone or/and in combination. Adding
an effervescent mixture of sodium bicarbonate and critic acid provided floating (formu-
lation not shown). Polymers and the effervescent mixture were blended in a mortar. Using
direct compression technology, floating layers were compressed at compression forces of
39.2–49.0 kN in a single tableting hand press with a 12-mm flat plain punch diameter
(Cadmach Machinery, India). Before compression, 0.2% magnesium stearate was added
as lubricant. Each layer formulation was blended and compressed (100 tablets) and test-
ed for hardness (n = 10), mass variation (n = 20) and floating behavior (n = 6). The hard-
ness of floating layers was in the range (49.0–58.8) × 104 N m–2 on a Monsanto Hardness
Tester (Nirmal Instrument, India). The mass of floating layer was 200 ± 10 mg.
Bilayer floating matrix tablet. – HPMC-K15M, PVP-K30 and Carbopol 934p were em-
ployed in the release layer formulation for the controlled delivery of captopril. Various
formulations of BFT are given in Table I. Matrix tablets were prepared by direct com-
pression technology. To each layer, 0.2% magnesium stearate was added as lubricant be-
fore compressing into the tablet. At the beginning, the optimizing floating layer (FD2)
was placed in the dye cavity and preparatory pressing was done. Thereafter, a release
layer formulation was added and subjected to compression force of 39.2–49.0 kN m–2. Each
BFT formulation was compressed (100 tablets) and subjected to testing for mass varia-
tion (n = 20), hardness (n = 10), drug content (n = 6), floating behavior (n = 6), and in vi-
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tro dissolution (n = 3). Hardness of the tablets ranged from (49.0–58.8) × 104 N m–2 on a
Monsanto Hardness Tester and the thickness was of 3.78 ± 0.13 mm.
Floating behavior
Floating behavior studies were performed on both the floating layer and BFT, car-
ried out in a USP 23 paddle apparatus 2 (10) at a paddle speed 50 rpm in 900 mL SGF
(pH 1.2, no enzyme) at 37 ± 0.2 °C for 24 h to mimic in vivo conditions. The following pa-
rameters were determined: the time needed to go upward and float on the surface (float-
ing lag time), floating duration and relative matrix integrity. The latter parameter was
determined on the basis of mass loss by gravimetry and visual inspection after the float-
ing studies.
In vitro dissolution
The captopril release from different BFT formulations was determined using a USP
23 paddle apparatus 2 (10) under sink condition. The dissolution medium was 900 mL
SGF (pH 1.2, no enzyme) at 37 ± 0.2 °C; paddle speed 50 rpm, to simulate in vivo conditions.
All experiments were done in triplicate and average values were taken. The formulation
prepared was subjected to dissolution tests for 24 h. Sample (4 mL) was withdrawn at
predetermined time intervals, filtered through Whatmann filter paper and replaced by
an equal volume of dissolution medium. Drug content in the dissolution sample was de-
termined by HPLC. Dissolution data were corrected for the dilution effect (11) and tablet
density was determined by the benzene displacement method before and after floata-
tion.
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Floating FD2 160 20 20 – – – –
Release RH1 – – – 25.0 25 – –
RH2 – – – 50.0 25 – –
RH3 – – – 75.0 25 – –
RH4 – – – 100.0 25 – –
RH5 – – – 125.0 25 5.0 –
RJ1 – – – 120.0 25 12.5 –
RJ2 – – – 112.5 25 20.0 –
RJ3 – – – 105.0 25 27.5 –
RJ4 – – – 97.5 25 35.0 –
RJ5 – – – 90.0 25 5.0 –
RK1 – – – 75.0 25 5.0 12.5
RK2 – – – 75.0 25 5.0 25.0
RK3 – – – 75.0 25 5.0 37.5
HPLC analysis
Quantitative determination of captopril was performed by HPLC. A gradient HPLC
system (Shimadzu HPLC Class VP series, Shimadzu, Japan) with two LC 10AT VP pumps,
a variable wavelength programmable UV-Vis detector SPD-10A VP, a system controller
SCL-10AVP and RPC-18 column (150 mm ´ 4.6 mm I.D., particle size 5 mm, Merck, Ger-
many) was used. The HPLC system was equipped with the software Class VP series ver-
sion 5.0 (Shimadzu). Quantitation was performed according to the earlier reported method
with a slight modification (12). The mobile phase consisted of n-propanol/phosphate
buffer (pH 3.0, 0.4% triethylamine), 20:80 (V/V). The filtered mobile phase was pumped
at a flow rate of 0.6 mL min–1. 20 mL of sample was injected into the column and the re-
tention time of captopril was found to be 4.0 min. The elute was detected by UV at 240 nm.
Stability
To assess the drug and formulation stability, stability studies were done according
to ICH and WHO guidelines (13). Optimized BFT (RK3), sealed in aluminum packaging
coated inside with polyethylene, and various replicates were kept in the humidity cham-
ber maintained at 45 °C and 75% RH for 3 months (Yorco Scientific Industries, India). At
the end of studies, samples were analyzed for the drug content, in vitro dissolution, flo-
ating behavior and other physicochemical parameters.
In vivo X-ray studies
The in vivo X-ray studies were approved by the institutional ethical committee vide
project No. JH/Pharmaceutics/11/2002 and performed on 10 healthy human volunteers
(Majeedia Hospital, Delhi, India). Volunteers aged 18–25 years and weighing 50–60 kg
were selected for these studies. Before participation of human volunteers in these stud-
ies, a written consent was obtained from them and an expert radiologist and physician
supervised the studies. BFT (RK3) was modified by adding 20 mg X-ray grade barium
sulfate (this amount was determined experimentally to allow X-ray visibility but not to
shun floatation of the tablet) in the release layer and excluding the captopril. A labeled
tablet was given to every subject with 200 mL water after overnight fasting (water was
available ad libitum) and after an hour interval a glass of water was given to the subject,
after tablet ingestion. Gastric radiography was done at 0, 2, 4, 6 and 8 h. Duration of the
tablet in the stomach was determined.
RESULTS AND DISCUSSION
First, the floating layer was prepared and evaluated on the basis of floating behavior
studies. It contained the effervescent mixture and K-grade HPMC to retain the carbon
dioxide produced from the effervescent mixture. From the results of floating behavior
studies (results not shown), it was found that as the concentration of effervescent mix-
ture increased, the floating lag time, floating duration and matrix integrity decreased and
vice versa. A reverse trend was observed on increasing the polymer concentration. There-
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fore the concentration of the effervescent mixture was chosen so as not to compromise
the matrix integrity with the possible shortest lag time and floating duration of up to 24
h. The optimized floating layer formulation (FD2 shown in Table I) had the floating lag
time of 3 min, good matrix integrity and floating duration of more than 24 h. The float-
ing layer for the development of BFT was found to be HPMC-K100M 80%, sodium bicar-
bonate 10% and citric acid 10%. BFT was prepared, containing the optimized floating
layer (FD2) and release layer containing captopril (25 mg) and various polymers alone
and/or in combination. BFT containing HPMC-K15M in the release layer (RH1, RH2,
RH3, RH4 and RH5) showed the initial burst effect and decreased final release rate. This
biphasic pattern of drug release is characteristic of matrix diffusion kinetics (14). As the
concentration of HPMC-K15M increased, not only the burst effect but also the final re-
lease rate decreased (Fig. 1). This could be due to the increased path length for the drug
to diffuse from the matrix. Furthermore, formulation containing HPMCK-15M and PVP-
-K30 in the release layer (RJ1, RJ2, RJ3, RJ4 and RJ5) showed that not only the final re-
lease rate but also the burst effect increased (Fig. 1). This was due to the fact that PVP-
-K30, which is hydrophilic in nature, allowed easy penetration of the medium into the
matrix and a more rapid release of captopril. Moreover, formulations containing HPMC-
-K15M, PVP-K30 and Carbopol 934p in the release layer (RK1, RK2, and RK3) showed a
more controlled release profile (Fig. 1). Initial burst effect decreased and the final release
increased with the Carbopol 934p concentration. This was because of the fact that Car-
bopol 934p which has pKa of 6.0, remains unionized in the acidic environment of disso-
lution medium. Therefore the release rate was controlled by HPMC-K15M and PVP-K30,
with the particles of Carbopol 934p acting as a physical barrier to drug release (15).
To analyze the captopril release mechanism as well as to select the BFT formulation
for in vivo studies, the in vitro release data were fitted into various release equations and
kinetic models [first order (16), zero order, Higuchi (17) and Korsmeyer and Peppas
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Fig. 1. Cumulative percentage of captopril released versus time (mean ± SD, n = 3).
(18)]. The RK3 BFT was chosen as the optimized formulation because it showed more
linearity between the cumulative percentage captopril released versus time, as indicated
by the highest value of the correlation coefficient R or R2 in all the selected models,
among all BFT formulations, and best fitted both Higuchi (R2 = 0.987) and zero order (R2
= 0.983) model. In the optimized BFT formulation (RK3) floating layer was found to be:
HPMC-K100M 46.7%, citric acid 5.8%, sodium bicarbonate 5.8%; release layer: captopril
7.3%, HPMC-K15M 21.9%, PVP-K30 1.5% and Carbopol 934p 10.9% (density 1.30 and
0.75 g cm–3 before and after floatation, respectively).
As indicated by the value of R2, the Higuchi model was found to be efficient in de-
scribing the kinetics of captopril release from the BFT formulation, with drug release be-
ing proportional to the square root of release time. To explore the release pattern, results
of the in vitro release data of optimized BFT (RK3) were fitted to the Korsmeyer and
Peppas equation (Mt/M¥ = k tn, where Mt/M¥ is the fraction of drug released after time
t in respect to amount of drug released at infinite time, k is the rate constant and n is the
diffusional exponent) (19) which characterize the transport mechanism. The value of n
was 0.392 (R2 = 0.995), indicating release governed by Fickian diffusion.
In view of the potential utility of the formulation, stability studies were carried out
at 45 °C and 75% RH for three months (climatic zone IV condition for accelerated test-
ing) to assess their long-term (2 years) stability. The protocols of stability studies were in
compliance with the guidelines in the WHO document (13) for stability testing of pro-
ducts intended for the global market. After storage, the formulation was subjected to a
drug assay, floating behavior and in vitro dissolution studies. The statistical analysis of
the parameter dissolution efficiency (20) of dissolution data (Table II), floating behavior
and drug content (Table III) after storage at 45 °C and 75% RH for three months showed
no significant change by Student’s t-test indicating that BFT formulation (RK3) could
provide a minimum shelf life of 2 years.
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Table II. Captopril released from optimized BFT (RK3)
Time (h) Captopril released (before storage, %)b Captopril released (after storage, %)a,b
2 12.0 ± 0.4 11.4 ± 1.6
4 19.2 ± 1.8 18.0 ± 2.9
6 29.5 ± 2.3 29.4 ± 4.9
8 37.8 ± 0.8 37.9 ± 4.3
10 50.1 ± 1.2 49.8 ± 3.4
12 60.4 ± 4.3 59.5 ± 0.8
14 67.4 ± 3.3 65.9 ± 1.6
16 75.3 ± 4.3 74.6 ± 2.4
18 81.5 ± 2.2 80.5 ± 3.9
20 89.2 ± 1.3 87.9 ± 1.6
22 92.8 ± 1.8 91.2 ± 4.3
24 94.4 ± 4.8 92.5 ± 1.5
a Storage at 45 °C/75% RH for three months.
b Mean ± SD, n = 3.
After ingestion of the final placebo formulation developed by using barium sulpha-
te in the release layer, the duration the tablet in the stomach and upper part of the intes-
tine was monitored by radiograms (Fig. 2). It was found that the tablet stayed in the
stomach for 6.4 ± 0.8 h.
CONCLUSIONS
The present study was carried out to develop the floating drug delivery with con-
trolled release of captopril using HPMC, K-grade polymer as a carrier. In vitro dissolu-
tion studies showed controlled release for 24 h, followed by the Higuchi diffusion mech-
anism and in vivo studies indicated increased GRT. Thus, results of the current study
clearly indicate, a promising potential of the captopril floating system as an alternative
to the conventional dosage form. However, further clinical studies are needed to assess
the utility of this system for patients suffering from hypertension.
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a Storage at 45 °C/75% RH for three months.
b Mean ± SD, n = 6 (floating and drug content studies), n = 10 (hardness test).
Fig. 2. X-ray radiogram of abdomen 6 h after ingestion of optimized placebo BFT formulation.
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S A @ E T A K
Dizajniranje i evaluacija dvoslojnih plutaju}ih tableta kaptoprila
ZIYAUR RAHMAN, MUSHIR ALI i RK KHAR
U radu je opisana priprava dvoslojnih plutaju}ih tableta (BFT) kaptoprila metodom
izravne kompresije. Plutaju}i dio tablete izra|en je iz HPMC, K-sloja i efervescentne
smjese limunske kiseline i natrijevog bikarbonata. Sloj s aktivnom supstancijom sadr`i
kaptopril i razli~ite polimere kao {to su HPMC-K15M, PVP-K30 i Carbopol 934p, sam ili
u smjesi s ljekovitom tvari. Sposobnost plutanja i in vitro osloba|anje ispitivano je u apa-
raturi 2 prema USP 23 u simuliranom `elu~anom soku (bez enzima, pH 1,2). Iz priprav-
ljenih tableta oslobodilo se pribli`no 95% ljekovite tvari tijekom 24 h u navedenim in vitro
uvjetima, a zastojno vrijeme bilo je 10 min. Tablete su plutale tijekom cijelog pokusa.
Pripravak je slijedio Higuchijev model osloba|anja. Za vrijeme skladi{tenja na 45 °C/75%
RH nisu uo~ene nikakve zna~ajne promjene u izgledu, sadr`aju ljekovite tvari, sposob-
nosti plutanja i osloba|anju kaptoprila u in vitro uvjetima. Placebo pripravci s barijevim
sulfatom u sloju za osloba|anje davani su volonterima. In vivo pokusi s rentgenskim
zra~enjem pokazali su da BFT pripravci imaju zna~ajno produljeno vrijeme zadr`avanja
u `elucu.
Klju~ne rije~i: dvoslojne plutaju}e tablete, HPLC, Higuchi, rentgensko zra~enje
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